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Abstract
During apoptosis, cells are fragmented into sealed packages for safe disposal by phagocytosis, a process requiring major reorganisation
of the cytoskeleton. The small p21 GTPase-activated kinases (PAKs) have been implicated in regulating cytoskeletal dynamics and a subset
are activated by caspase 3/7 cleavage. However, the functional importance of this activation in apoptosis remains unknown. Using early
Xenopus embryos, we have dissected xPAK1 activation from other causative events in apoptosis. An apoptotic-like cell fragmentation was
observed 30 min after expression of the xPAK1 catalytic domain and occurred in the absence of other markers of apoptosis. In vitro,
activated xPAK1 phosphorylated the regulatory light chain (xMLC) of myosin II at threonine 18 and serine 19, events known to activate
the actin-dependent ATPase of cytoskeletal myosin. In vivo, activated xPAK1 induced hyperphosphorylation of xMLC. BDM, a myosin
inhibitor, and ML-7, a MLCK inhibitor, both abrogated cell fragmentation induced by activated xPAK1, and ML-7 also inhibited xPAK1
activity. Endogenous xPAK1 was cleaved during normal apoptosis and this was associated with xPAK1 activation and increased serine 19
phosphorylation of xMLC. The data show that PAK activation is sufficient for apoptotic body formation in vivo and strongly suggest that
activation of myosin II is essential for this process.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Apoptosis was originally identified (Kerr et al., 1972) as
a specific type of cell death involving distinct morphologi-
cal changes and a stepwise degradation of the cell. These
authors described apoptotic cells as first exhibiting a con-
densation and fragmentation of nuclear chromatin. This is
followed by a process of “budding,” during which the cy-
toplasmic membrane releases subcellular fragments or ves-
icles, referred to as apoptotic bodies, each enclosed by an
intact cortical membrane. Finally, the apoptotic fragments
undergo a process of disintegration called secondary necro-
sis. Though recent work suggests that these events may not
always occur in a strict order (e.g., Song and Steller, 1999),
genetic studies of programmed cell death (Peter et al., 1997)
have shown that cell death by apoptosis depends on a
precisely controlled cascade of events. Apoptosis can be
initiated by several distinct mechanisms of which signal
transduction via the Fas and TNF “death” receptors are the
best studied. Stimulation of these receptors leads to the
activation of a cascade of proteases, the caspases. Level 1
caspases appear to be direct targets of the death signal and
these activate the level 2 or downstream caspases, such as
caspase 3 and 7. Subsequent caspase cleavage of many
cellular proteins leads to their activation or inactivation. It is
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this third level of the cascade which leads to the visible
processes of cell fragmentation and death by apoptosis.
The p21GTPase Activated protein Kinases (PAKs) are
signal transduction kinases of the Ste20 kinase family
(Brown et al., 1996; Frost et al., 1996; Rooney et al., 1996)
implicated in regulating the actin cytoskeleton (Dhar-
mawardhane et al., 1997; Harden et al., 1996; Manser et al.,
1997; Sells et al., 1997). Activated PAK has been shown to
phosphorylate several substrates, including myosin light
chain kinase (MLCK), LIM-kinase, myosin regulatory light
chain (MLC) (and a possibly homologous phosphorylation
of myosin I from lower eukaryotes), Raf1, and MEK1 of the
MAP-kinase cascade (Daniels and Bokoch, 1999). PAK
phosphorylation of MLCK leads to its inactivation, while
PAK phosphorylation of LIM-kinase leads to its activation,
promoting actin polymerisation via the inactivation of co-
filin. Under certain circumstances, the PAKs have been
shown to activate the the so-called stress kinases JNK/
SAPK1 (jun N-terminal kinase/stress activated protein ki-
nase 1) and p38/Hog/SAPK2, (Bagrodia et al., 1995; Brown
et al., 1996; Zhang et al., 1995), though the mechanism of
this activation is unknown. Although the six known mam-
malian PAKs are fairly homologous, they can be grouped
into two major families according to their noncatalytic N-
terminal sequences (Bokoch, 2003; Jaffer and Chernoff,
2002). PAKs 1 to 3 form a subfamily whose N-terminal
sequences are quite similar, and all three interact with and
are activated by GTP-bound Cdc42 and Rac. To date, in
Xenopus, four PAKs have been identified, probably corre-
sponding to the mammalian PAKs 1, 2, 3, and 5 (Cau et al.,
2000, 2001; Faure et al., 1997; Souopgui et al., 2002). As in
mammals, xPAK1 and 2 are very similar to each other and
both show an equal degree of homology with mammalian
PAK1 and 2, making it difficult to decide whether xPAK1
is isogenic with mammalian PAK1 or PAK2, but see below.
xPAK1 has also been shown to interact with Cdc42 and Rac
but not Rho (Faure et al., 1997; and N.I., L.P., T.M., un-
published data), the equivalent data for xPAK2 are presently
unavailable.
During apoptosis, the human hPAK65 and hPAK2, two
very close homologues, and Xenopus xPAK1 but not
hPAK1 have been shown to be activated by level 2 caspases
via the release of their catalytic domains from an N-terminal
inhibitory sequence (Faure et al., 1997; Lee et al., 1997;
Rudel and Bokoch, 1997). This also suggests that xPAK1
may in fact be the functional homologue of hPAK2. Over-
expression of the catalytic domain of hPAK65 promoted
apoptosis with concomitant cell rounding up and shrinkage
and, in some cases, the activation of JNK (Lee et al., 1997).
Consistent with a requirement for hPAK2 in apoptosis, a
dominant negative hPAK2 inhibited the production of apo-
ptotic bodies (Rudel and Bokoch, 1997). On the other hand,
a dominant negative form of xPAK1 promoted apoptosis in
Xenopus oocytes (Faure et al., 1997), and more recently,
PAKs have been shown to provide an important survival
signal by inactivating BAD (Gnesutta et al., 2001; Jakobi et
al., 2001; Schu¨rmann et al., 2000). Thus, on the one hand,
full-length PAKs transduce an important survival signal,
while on the other hand, once cleaved by caspase, PAK
promotes apoptotic cell death. However, none of the known
PAK substrates have been shown to promote apoptosis.
Thus, the role PAK activation plays in apoptosis is still a
mystery.
To resolve this problem, we have taken the novel ap-
proach of expressing the catalytic domain of xPAK1 in
early Xenopus embryos. Unlike most other cellular systems,
including Xenopus oocytes, Xenopus embryos are refrac-
tory to the onset of apoptosis prior to the midblastula tran-
sition (Sible et al., 1997; Stack and Newport, 1997). Hence,
early Xenopus development provides an opportunity to test
the in vivo activities of individual proapoptotic factors in
isolation from the complete apoptotic cascade. Our results
lead to the novel conclusion that the activation of PAK by
its caspase cleavage is sufficient for apoptotic body forma-
tion. The data also strongly suggest that apoptotic body
formation is the direct result of myosin II activation by
PAK.
Materials and methods
xPAK1 constructions, in vitro transcription, and embryo
microinjection
The xPAK1 cDNA (Faure et al., 1997; Islam et al., 2000)
encoding amino acids 2 to 527 (pTSxPAK1) or 159 to 527
(pTSxPAKTrunc) was subcloned into pT7TS (P. Krieg)
in-frame with an N-terminal HA1-epitope (Wilson et al.,
1984) or a C-terminal Myc-epitope (-EQKLISEEDL). Ly-
sine 281, flanking the ATP binding domain, was mutated to
alanine to produce N-K281A (pTSxPAKTruncM4), a ki-
nase dead form of N159. Several mutations were also
introduced into the full-length pTSxPAK1; prolines 13 and
14 of the putative Nck SH3 binding site were mutated to
alanine producing P13/14A and the activating mutations
leucine 98 to phenylalanine (L98F) adjacent to the GTPase
Binding Domain and threonine 405 to glutamic acid
(T405E) in the kinase domain activation loop. Membrane
targeting of full-length xPAK1 was achieved by adding the
C-terminal extension -LEPPETQPKRKCCIF from human
Cdc42 to produce xPAK1-CAAX. Capped RNA was tran-
scribed from the linearized pTSxPAK constructions using
T7 (sense transcripts) or Sp6 (antisense transcripts) poly-
merase (mMESSAGE-mMACHINE, Ambion), and 2–4 nl
of RNA in water was injected into one blastomere of two-
cell Xenopus embryos. Eggs were recovered in MMR (0.1
M NaCl, 2 mM KCl, 1 mM MgSO4, 2 mM CaCl2, 5 mM
Hepes, 0.1 mM EDTA, pH 7.8), in vitro fertilized, injected
in 0.2 MMR, 5% Ficoll (Amersham Biosciences), and
then cultured in 0.1 MMR at 18°C. RNA encoding the
activated form of MEKK1 (MEKK1Dnmyc in pXT7) was
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transcribed from pXT7-MEKK1Nmyc (kindly provided
by S. Sokol).
The cDNA encoding amino acids 2 to 527 of xPAK1 was
also subcloned into pGEX2T (Amersham Biotech) and used
to express a GST-fused recombinant form of the protein,
which was isolated on G-Sepharose (Amersham Biotech)
(Smith and Corcoran, 1991).
Antibodies
Affinity-purified antibodies against Xenopus MLC (also
known as Regulatory Light Chain) were prepared by A.
Bresnick, those against Phospho-S19 MLC were obtained
from Cell Signaling Technology Inc. (product #3671), and
affinity-purified antibodies against Xenopus MHC-A and-B
were kindly supplied by R. Adelstein (Bhatia-Dey et al.,
1993). Rabbit polyclonal antibodies were raised against the
N-terminal 65 a.a. of xPAK1 and affinity purified on the
CNBr-Sepharose immobilized peptide. Polyclonal anti-
ERK2 antibody was kindly provided by J. Grose and raised
to the C-terminal 24 a.a. of Xenopus ERK2 (e.g., Ste-
fanovsky et al., 2001). The anti HA-1 monoclonal antibody
12CA5 was obtained and used as an ascites supernatant.
Active caspase 3 was detected by using an Asp175 cleav-
age-specific antibody (Cell Signaling Technology Inc. prod-
uct #9661).
Embryo extracts and kinase assays
Where stated, embryos were injected with in vitro tran-
scribed capped message in order to express the different
xPAK1 constructs. The expressed proteins were then recov-
ered by immunoprecipitation via their N-terminal HA-1 or
C-terminal Myc epitope tag for use in kinase assays as
follows. Total protein extracts from injected and uninjected
embryos were first prepared by homogenizing embryos (20
embryos/100 l) in MGE, (20 mM MOPS, pH 7.0, 10%
glycerol, 0.5 mM EDTA, 5 mM EGTA, 1 mM NaVO4, 5
mM NaPPi, 50 mM NaF, 80 mM -glycerophosphate, 1%
Triton X-100, 1 mM benzamidine, 1 mM DTT, 1 mM
PMSF), by repeated rapid aspiration with a micropipette
and were then centrifuged at 120,000g for 15 min. The clear
supernatant was collected and rapidly frozen and stored at
80°C.
To isolate the expressed proteins, 25 l of embryo su-
pernatant was diluted to 60 l with MIKI, (20 mM Tris–
HCL, pH 7.5, 150 mM NaCl, 0.1 mM EDTA, 1 mM EGTA,
1 mM MgCl2, 1 mM NaVO4, 1% Triton X-100, 1 mM
PMSF), 5 l anti-HA-1 ascites (12CA5), or 5 l anti-Myc
ascites (Sigma) was added and after 60 min incubation on
ice, 10 l of a 50% protein A-Sepharose slurry (Pharmacia)
in MIKI was added and the incubation continued for another
30 min. The slurry was then washed three times in 500 l
MIKI and used immediately in the phosphorylation (kinase)
reaction, below.
XPAK kinase assay
The protein A-Sepharose was resuspended in one vol-
ume (20 l) of D2X (50 mM Hepes, pH 7.4, 50 mM
-glycerolphosphate, 50 mM MgCl2, 0.2 mM NaVO4, 4
mM DTT, 75 M [-32P]ATP (5000 dpm/pmol)) contain-
ing 50 ng of myelin basic protein (MBP) (GibcoBRL) or
10–30 ng recombinant MLC and incubated for 30 to 60 min
at 30°C.
Endogenous JNK assay
Embryo supernatant (25 l) was adsorbed to 3 g glu-
tathione-Sepharose immobilized GST-c-Jun in 40 l of
MIKI for 30 min on ice. The Sepharose was washed three
times with 300 l of MIKI, resuspended in one volume (20
l) of 0.5 MPM [15 mM MOPS, pH 7.5%, glycerol, 60
mM p-nitrophenylphosphate, 15 mM MgCl2, 1 mM DTT,
0.1 mM PMSF, 150 M [-32P]ATP (3000 dpm/pmol)] and
incubated for 30 min at 30°C. After electrophoresis on 12 %
polyacrylamide-SDS, relative substrate incorporation was
quantified on a STORM 860 phosphorimager (Molecular
Dynamics). As a positive control of JNK activation, two-
cell embryos were injected with capped transcripts encoding
activated MEKK1N, extracts prepared 3.5 h after injec-
tion, and JNK activity was assayed as described above.
ERK2 assays were performed by mobility shift on a 10%
SDS polyacrylamide gel (bisacryl:acryl::30:0.2) and de-
tected by using an anti-Xenopus ERK2 antibody (J. Grose).
Induction of apoptosis and xPAK1 cleavage
Apoptosis was induced by treating embryos with 30 mM
hydroxyurea (Sigma) from the two-cell stage through the
midblastula transition to 10 or 11 h postfertilization or, for
the preparation of apoptotic extracts and analysis of endog-
enous xPAK1 cleavage, to the equivalent of stage 12 (18 h
postfertilization) (Stack and Newport, 1997). In order to
analyze xPAK1 cleavage, 35S-methionine-labeled xPAK1-
Myc was prepared by coupled in vitro transcription/trans-
lation (Promega) and incubated with a whole protein extract
from apoptotic and normal embryos prepared as above. To
measure xPAK1 activation, C-terminally Myc-tagged
xPAK1 was expressed in embryos by RNA injection and
recovered by anti-Myc immunoprecipitation for kinase as-
says. The immunoprecipitate was then incubated for 5 h
before being washed with MIKI and assayed for xPAK1
with protein extract kinase activity on MLC as substrate as
described above.
Caspase assays
Wild type HA-xPAK1 was expressed in embryo and
immunoprecipitated with anti-HA-1 antibody from 10 l
embryo supernatant. The immobilized kinase was resus-
pended in 13 l of 20 mM PIPES, pH 7.2, 100 mM NaCl,
10 mM DTT, 1 mM EDTA, 0.1% CHAPS, 10% sucrose, 40
ng recombinant caspase 7 was added, and the reaction was
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incubated for 30 min at 30°C. The products of cleavage
were detected with a polyclonal antibody raised against
amino acids 1 to 65 of xPAK1. Alternatively, embryo ex-
tracts were analyzed by SDS-PAGE–Western blot using an
activated caspase 3-specific antibody (Cell Signaling Tech-
nology Inc. #9661) as described by the suppliers.
DNA analysis
Embryos were lysed in 10 mM Tris–HCl, pH 8.3, 1 mM
EDTA, 1% SDS, digested with 1 mg/ml proteinase K for 30
min at 37°C, phenol/chloroform extracted, ethanol precipi-
tated, and finally digested at 37°C with 1 mg/ml RNase A
before fractionation on 2% agarose.
In vitro and in vivo phosphorylation of myosin II
To identify xPAK1 substrates, standard xPAK kinase
assays (see above) were performed, but 3 l of uninjected
embryo extract was added as substrate and washes of the
immunoprecipitated kinase were made in 0.5 M NaCl, 25
mM Tris-HCl, pH 8.0, 10 mM EGTA, 5 mM EDTA, 50 mM
NaF, 50 mM Na4P2O7, 1% Nonidet P40 (Sigma) followed
by a single wash in MIKI. Assays were also performed by
using as substrate 1 g of homogeneous recombinant
xMLC, xMLC-S19A, or xMLC-TS18/19AA (0.25 l in 5
mM KPO4, pH 7.0, 2 M urea, 1 mM DTT, and 0.02% NaN3)
or 1 g of native Xenopus myosin II. Myosin II was ex-
tracted and chromatographically purified to near homoge-
neity from Xenopus eggs as described previously (Kelley et
al., 1995). The purified Xenopus myosin II was either added
in native form in 0.5 M NaCl, 15 mM Tris-HCl, pH 7.5, 1
mM EDTA, 5 mM DTT or diluted to 1 M urea after
denaturation in 8 M urea.
To determine whether expression of N159 in vivo
caused changes in the phosphorylation state of endogenous
myosin II, embryos were injected with 1.5 ng of N159 or
N-K281A RNA and 75 nCi of [-32P]ATP (NEN). After
3 h incubation, embryos were homogenized and myosin II
immunoprecipitated as previously described (Kelley et al.,
1996) using antibodies specific for Xenopus MHC-A or
MHC-B (a kind gift from R. Adelstein). Under these con-
ditions, neither the anti-MHC-B antibody nor a nonspecific
rabbit IgG (Sigma) precipitated detectable amounts of
xMHC-A. Immunoprecipitates were separated on 5–20%
SDS polyacrylamide gradient gels, transferred to nitrocel-
lulose membrane (Hybond C, Amersham), exposed to
record the 32P incorporation, and then the same membrane
was probed with both anti-MHC-A and anti-xMLC antibod-
ies to exactly colocalize these peptides with the radiolabeled
bands. Recovery of xMLC was quantitated on the same
transfers by comparison with gel loadings of known
amounts of recombinant xMLC. The absolute 32P incorpo-
ration in dpm was determined from the phosphorimager
data by comparison with a range of known dpm of an
unrelated 32P-labeled protein. This allowed an absolute es-
Fig. 1. (A) The structure of xPAK1 in comparison with mammalian
PAK2 (mPAK2) and of the N-terminal truncation mutants N159 and
N-K281A. The Cdc42/Rac1 GTPase Binding Domains (G.B.D.), Au-
toinhibitory Domain, Acidic Domain, and Caspase cleavage sites of
mPAK2 and xPAK1 are indicated. The positions of the SH3 domain
binding sites for the adapter protein Nck and for the PIX(Cool) family
of nucleotide exchange factors (GEFs) in mPAK2 and the probable
position of their potential equivalents in xPAK1 (dashed) are indicated
(Daniels and Bokoch, 1999; Bokoch, 2003). (B) Injection of 500 pg of
N159 leads to a rapid displacement and internalization of embryonic
pigment and (C) to secondary necrosis by blastula stage 8 (Nieuwkoop
and Faber, 1967). In both (B) and (C), the leftmost panels show
uninjected embryos at the same stage. (D) The effect of N159 is
dosage-dependent. The lowest embryo in the leftmost panel is essen-
tially wild type. (E) Coinjection of a 3 times excess of antisense
N-K281A RNA with 500 pg of N159 RNA significantly suppressed
the phenotypic effects of N159 as compared with the coinjection of
the same excess of N-K281A sense RNA (also see Table 1). The
embryo in the left top corner of the right panel is essentially wild type.
(F) Coinjection of antisense RNA also caused a reduction in both
N159 protein concentration (upper panel) and kinase activity (lower
panel) in blastula embryos. N159 was detected by the ECL protocol
(NEN) using an anti-HA-1 epitope antibody. MBP, myelin basic protein.
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timate of 32P dpm/ng of xMLC. Calculation of the phos-
phorylation stoichiometry was then made assuming an em-
bryonic volume of 0.5 l and an ATP pool of 1 mM.
Phosphorylation of endogenous MLC during apoptosis
was monitored by Western Blot using an anti-Phospho-S19-
MLC antibody (Cell Signalling) as recommended by the
manufacturers. Before SDS-PAGE, myosin II from whole
embryo lysates was enriched by selective precipitation with
NH4SO4 (Kelley et al., 1996).
BDM treatment
2,3-butanedione monoxime (BDM) (Sigma-Aldrich) was
prepared immediately before use in 0.1 MMR at 10, 30,
100, or 300 mM, as indicated, and embryos were transferred
to this solution at the two-cell stage immediately after in-
jection or at the midblastula transition (8 h postfertilization)
for embryos treated with hydroxyurea.
ML-7 injection
ML-7 (Calbiochem) was injected to give the final em-
bryo concentrations indicated, assuming an embryonic vol-
ume of 1 l.
Results
Four Xenopus PAKs have been identified to date and
classified by their overall homologies with mammalian
PAKs as xPAK1, 2, 3, and 5 (Cau et al., 2000, 2001;
Faure et al., 1997; Souopgui et al., 2002), though xPAK1
and 2 are in fact in evolutionary terms both equidistant
from hPAK1 and from hPAK2. xPAK1 was shown to be
cleaved by caspase 3 in an analogous manner to hPAK2
but, though xPAK2 contains a potential caspase 3 site,
this site has not to our knowledge been tested. An N-
terminally truncated form of xPAK1, N159, was con-
structed to resemble the caspase cleavage product, which
lacks all the known functional N-terminal domains, in-
cluding the Cdc42/Rac GTPase Binding Domain (GBD),
containing the CRIB motif, and the N-terminal autoin-
hibitory domain (Zhao et al., 1998) (Fig. 1A). Injection
of N159 mRNA into two-cell Xenopus embryos (i.e.,
2 h postfertilization) led to a displacement and absorption
of animal pole pigment within 30 min to 1 h, and em-
bryos visibly began to disintegrate well before blastula,
stage 8 (8 h postfertilization, i.e., 4 –5 h postinjection)
(Nieuwkoop and Faber, 1967) (Fig. 1B and C). Injection
of 400 pg or more of N159 mRNA per embryo severely
affected survival to early gastrula, stage 10 (12 h post-
fertilization), while the injection of mRNA encoding wild
type (wt) xPAK1, the first 63 a.a. of xPAK1 or a kinase
dead form of N159 (N-K281A; Fig. 1), displayed no
deleterious effect (Table 1). The N159 effects were
dosage-dependent, and at 50 and 150 pg RNA, a large
fraction of embryos developing normally (Fig. 1D and
Table 1). Coinjection of antisense RNA significantly sup-
pressed the phenotype as well as levels of N159 protein
and associated kinase activity (Fig. 1E and F). This
demonstrated that the effect was specific, requiring the
N159 protein and more precisely its kinase activity.
Table 1















xPAK 1–63 1.5 ng 116 102 87 72 56 77
N159 1.5 ng 65 0 0 65 0 0
N159 0.5 ng 275 34 12 218 4 1
N159 0.4 ng 26 2 7 n/d n/d n/d
N159 0.15 ng 115 99 86 76 48 63
N159 0.05 ng 81 72 88 65 62 95
N-K281A 0.5 ng 127 123 96 127 123 96
xPAK1 wt 1.5 ng 383 308 80 281 206 73
N159 0.5 ng
and
N-K281A 1.5 ng n/d n/d n/d 100 47 47
N159 0.5 ng
and
AS N-K281A 1.5 ng n/d n/d n/d 113 113 100
“AS” refers to antisense RNAs. Two-cell Xenopus embryos were injected with the indicated amounts of RNAs encoding the different xPAK1 constructs.
Embryos were allowed to develop to gastrula stage 12 (18–19 h postfertilization) or to swimming tadpoles stages 40 to 41 (3–4 days postfertilization).
Survival was judged as detectable movements associated with gastrulation and by the continued development of swimming tadpoles irrespective of their
precise phenotypic damage. It should be noted that, in the case of antisense suppression of the N159 effects, coinjection of excess of N-K281A sense RNA
already limited the effect of N159 on survival, perhaps by limiting its translation. The coinjection of antisense RNA was, however, clearly more effective.
It should also be noted that only two of the surviving embryos displayed evidence of both head and tail structures when N159 and N-K281A sense RNAs
were injected, while most did when N159 was injected with the antisense RNA (see Fig. 1E).
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N159 induces cell fragmentation and the rearrangement
of cortical actin
Intermediate amounts of N159 induced “budding” of
embryo blastomeres within 30 min of injection (Fig. 2A and
B). When these embryos were stained with the DNA stain
TOPRO3 (Molecular Probes) and optically sectioned (De
Mazie`re et al., 1996), it became clear that, rather than
simply undergoing surface budding, the affected blas-
tomeres had in fact fully fragmented (Fig. 2C). At later
stages (Fig. 2D–F), the normal blastomeres, having contin-
ued to divide, were similar in size to the blastomere frag-
ments. While these normal bastomeres showed a clear nu-
clear staining, such staining was absent from the blastomere
fragments. The fragments did, however, show a meshwork-
like cytoskeletal autofluorescence resembling the normal
blastomeres (Fig. 2E and F).
Apoptotic bodies are encapsulated in an intact cortical
membrane (Martin et al., 1994). Since the Xenopus embry-
onic pigment is imbedded in an actin cortex, its displace-
ment prior to blastomere fragmentation (Fig. 1B), suggested
that N159 induced a rearrangement of cortical actin. When
Fig. 2. (A) The injection in the range of 200–500 pg of N159 RNA induced blebbing of the embryos by stage 6, seen enlarged in (B). An uninjected stage
6 embryo is shown for comparison in (A). (C) Consecutive optical sections, i through iv, of N159-injected embryos at stage 6.5 to 7 stained with TOPRO3
revealing DNA, but cell boundaries are also visible in autofluorescence, (obtained with a MRC5 confocal microscope; Biorad). Section i displays normal cell
and nuclear morphologies. (D) Optical section of a noninjected stage 8 embryo stained with TOPRO3 and (E) enlarged field showing normal cell boundaries
and nuclei. (F) Optical section of a stage 8, N159-injected, TOPRO3-stained embryo and (G) enlarged field of the same embryo. The fragmented region
of the embryo has partially detached revealing the structure of individual fragments. (H) F-actin (phalloidin)-stained freeze section of a normal stage 6 embryo
and (I–K) N159-injected embryos. (J) shows an enlarged view of (I) and (K), a section from a different embryo. “b” indicates the blastopore, “n” blastomere
nuclei, and “f ” blastomere fragments.
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N159-injected embryos were fixed, freeze-sectioned, and
stained for F-actin with phalloidin-texas red (Molecular
Probes) (Drechsel et al., 1997), blastomere fragments were
seen to be surrounded by a filamentous actin cortex that was
often significantly thicker than the cortex of normal blas-
tomeres (Fig. 2G–J). The large increase in the cortical actin
surface that of necessity resulted when blastomeres frag-
mented as well as the concomitant thickening of the cortical
actin around each fragment, suggested that N159 not only
induced major rearrangement of actin but also polymeriza-
tion of soluble actin.
As compared with N159, when full-length xPAK1 was
constitutively activated by L98F or T405E point mutations,
it showed little or no tendency to induce blastomere frag-
mentation (Fig. 3A–C). L98F did, however, partly disrupted
cell division and caused some pigment displacement. The
phenotypic effects of these mutants correlated well with
their relative activation levels (Fig. 3F). Targeting xPAK1
to the plasma membrane by addition of a C-terminal CAAX
motif led to the rapid reorganization of embryonic pigment
into a pattern of points (Fig. 3D and E), and subsequently to
a severe necrosis of embryos. [In the example shown, the
putative N-terminal Nck site was also mutated (P13/14A) to
ensure membrane recruitment solely via the CAAX motif.]
Though the overall catalytic activity of this mutant was in
fact less than that of L98F (Fig. 3F), membrane targeting
quite possibly facilitated access to targets such as cortical
actomyosin associated with the phenotypic effects observed
(see below).
Cell fragmentation is not accompanied by other signs of
apoptosis
First, N159 was coexpressed with wild type xPAK1
in embryo and its characteristic N-terminal caspase 3/7
cleavage product sought (Faure et al., 1997). Despite the
fact that full-length xPAK1 was expressed in the frag-
menting embryos at a very similar level to uncleavable
kinase dead N-K281A, and could be cleaved in vitro
with recombinant caspase 7, no trace of this characteristic
cleavage product was detected in embryo (Fig. 4A). A
highly sensitive detection of level 2 caspase activation
can now be achieved using antibodies specific for acti-
vated caspase 3 (Fig. 4B). While hydroxyurea treatment
of embryos did induce caspase 3 cleavage and activation
after the midblastula transition (stage 8) as reported
(Stack and Newport, 1997), track 2, we were completely
unable to detect caspase 3 activation in N159-injected
embryos, even 19 h after injection of 1.5 ng of N159-
expressing RNA. DNA degradation is another character-
istic of apoptosis (Martin et al., 1994). Embryos injected
with N159 or N-K281A mRNA and uninjected em-
bryos were allowed to develop until midblastula, stage 6
(3.5 h postinjection), or to the equivalent of late gastrula,
stage 12 (19 h postinjection), before their DNA was
extracted and analyzed (Fig. 4C). As expected from the
extent of early cell death, the N159-injected embryos
exhibited about a six times reduction in DNA content at
the equivalent of stage 12 when compared with N-
K281A-injected or uninjected embryos. However, in no
case was any degradation of DNA apparent. Externaliza-
tion of phosphatidylserine, a marker of the early mem-
brane changes associated with apoptosis (Martin et al.,
1995), was tested by using fluorescently labeled Annexin
V (ApoAlert Annexin V, Clontech) (Vermes et al., 1995)
with negative results (data not shown). We also tested
membrane integrity of the N159-injected and unin-
Fig. 3. Activation levels of xPAK1 mutants correspond qualitatively with
their abilities to induce blastomere fragmentation and pigment displace-
ment. (A–E) Embryos 2.5 h after injection with 0.5 ng of RNA encoding
the truncated N159 or the full-length mutants xPAK1-L98F, -T405E,
-P13/14A (Fig. 1A), and -P13/14A-CAAX (see Materials and methods).
(B) Extracts were prepared from the embryos shown in (A) 4 h after
injection and assayed for xPAK kinase activity using MBP as substrate as
described in Materials and methods.
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jected embryos using the vital dye Nile Blue (e.g., Jeffs
et al., 1992) with negative results (data not shown).
N159 does not activate JNK or ERK
Both the activation of JNK and the inhibition of the
mitogen-activated protein kinase ERK may play roles in the
induction of apoptosis (Chen et al., 1996; Liu et al., 1996).
There have been various conflicting reports of JNK activa-
tion by the mammalian PAKs (Bagrodia et al., 1995; Brown
et al., 1996; Frost et al., 1996; Obermeier et al., 1998;
Teramoto et al., 1996), and PAK has been shown to coop-
erate in the hyperactivation of ERK (Frost et al., 1997). Fig.
4D shows that, even at the highest level of N159 expres-
sion, neither endogenous JNK nor endogenous ERK2 was
activated at stage 6, i.e., 3.5 h after injection and well after
fragmentation had become evident. At the same stage, JNK
could be activated by the expression of a constitutively
active form of the JNK kinase kinase MEKK1 (MEKK)
(Fig. 4E). At the equivalent of stage 12, (18 h postinjection),
ERK2 still showed no activation, though a 2-fold activation
of JNK was evident. This latter activation was probably an
indirect result of necrosis which had extended throughout
the embryo by this stage.
Activated xPAK1 phosphorylates the regulatory light
chain of myosin II in vitro
To identify possible phosphorylation targets of the cata-
lytic domain of xPAK1, N159 was immunoprecipitated
from injected embryos and used to phosphorylate a total
soluble embryo protein extract (Materials and methods).
Though this extract contained many endogenous kinases,
giving rise to a large number of phosphorylated bands on
SDS-PAGE and somewhat limiting its usefulness, when
N159 was added, phosphorylation of two additional pep-
tides was clearly observed, one of 20 kDa and one of 50
kDa. The latter band corresponded to the size of the N159
kinase itself, while no band of phosphorylation correspond-
ing to the molecular weight of actin (44 kDa) was observed.
Myosin regulatory Light Chain (MLC) is a 20-kDa protein
that was previously shown to be an in vitro substrate for
activated PAK isoforms (Ramos et al., 1997; Tuazon and
Traugh, 1984). Thus, it was possible that the 20-kDa band
observed in Fig. 5A was Xenopus MLC (xMLC). Conven-
tional nonmuscle myosin II is a major component of the
actin cytoskeleton and is implicated in cytokinesis, stress
fiber formation, cortical actin organization, and in secretion
(e.g., Mitchison and Cramer, 1996). Myosin II is a hexamer
consisting of two heavy chains (MHC) of about 220 kDa
two nonregulatory or essential light chains of about 17 kDa,
and two regulatory light chains (MLC) of 20 kDa. Xenopus
embryos contain two variants of xMHC: xMHC-A is the
predominant form but about 1% of myosin II contains the
slightly longer xMHC-B variant (Bhatia-Dey et al., 1993).
N159, but not N-K281A, was found to phosphorylate
a homogeneous preparation of recombinant xMLC (xMLC)
in vitro, and this phosphorylation was severely inhibited by
the mutation of serine 19 (S19A) (Fig. 5B). Phosphorylation
of serine 19 and to a much lesser extent of threonine 18 of
xMLC by myosin light chain kinase (MLCK) promotes
myosin polymerization and increases the actin-dependent
ATPase activity of myosin (Bresnick et al., 1995). These
phosphorylations are essential for the myosin-dependent
movement of actin filaments in vitro and for myosin func-
tion in vivo and are believed normally to be under MLCK
control. Close inspection of Fig. 5B shows that, in fact,
mutation of serine 19 did not completely eliminate phos-
phorylation of xMLC by N159. But when threonine 18
was also mutated, phosphorylation was no longer observed.
Thus, xPAK1 and MLCK display surprisingly similar sub-
strate preferences.
To determine whether N159 could also phosphorylate
xMLC within the native myosin II hexamer, myosin II was
purified from Xenopus eggs and used as substrate in in vitro
assays, again in comparison with the inactive N-K281A as
negative control. xMLC was found to be accessible to
N159 phosphorylation in the context of native Xenopus
myosin II (Fig. 5C). When urea denaturation was used to
liberate xMLC in a soluble form from myosin II, no increase
in its phosphorylation by N159 was observed, showing
that it was already fully accessible within the myosin II
hexamer (compare native and denatured xMLC  N159
tracks in Fig. 5C). Weak in vitro phosphorylation of
xMHC-A, the major MHC in Xenopus embryos, was also
observed, but occured at only at 10–15% of the level of
MLC phosphorylation. Consistent with the fact that the
MHC becomes insoluble after urea denaturation of myosin
II, the band of xMHC-A phosphorylation was no longer
observed after denaturation (compare xMHC-A/N159
tracks in Fig. 4C). Thus, xMLC of native Xenopus myosin
II was fully accessible to phosphorylation by N159 in
vitro.
Activated xPAK1 also phosphorylates myosin II in embryo
To investigate whether myosin II was also an in vivo
target of N159, embryos were injected with [32P]ATP
and N159 or N-K281A mRNA. After 3 h of develop-
ment, myosin II was extracted, immunoprecipitated with an
anti-MHC-A specific antibody, and analyzed by Western
blot and Phosphoimaging (Fig. 5D). Overexpression of
N159 led to a three-fold increase in the phosphorylation of
the xMLC coimmunoprecipitated with xMHC-A when
compared with injection of the kinase dead form N-
K281A (Fig. 5E). A significant, but smaller increase in
phosphorylation of the xMHC-A was also observed. Thus,
the in vivo data closely reproduced the observations of
myosin II phosphorylation made in vitro, suggesting that
indeed N159 directly phosphorylated xMLC and perhaps
also xMHC-A in embryo. A similar (3- to 5-fold) increase
in MLC phosphorylation has been previously correlated
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Fig. 4. Expression of the highly active catalytic domain of xPAK1 (N159) does not induce apoptosis. (A) N159 does not induce cleavage of xPAK1 in embryo.
(Left), 1.5 ng of RNA expressing HA-tagged N159 were coinjected with 1.5 ng of RNA expressing the caspase cleavable HA-tagged xPAK1 (wt) and embryos
incubated for 3 h. Total embryo extracts were then prepared, analyzed by SDS-PAGE, and probed for exogenous xPAK1 forms using monoclonal anti-HA-1
antibody. Neither overexposure of this gel nor that from an independent experiment gave any indication of the expected 24-kDa N-terminal caspase cleavage
fragment of xPAK1. Parallel kinase assays of exogenous N159/xPAK1 activity (using MBP as substrate) and endogenous JNK (using c-jun as substrate) are shown
below the panel (see Materials and methods). (Right) Caspase 7 cleavage of xPAK1. HA-tagged xPAK1 was expressed in embryos, isolated by immunoprecipitation
using the mouse monoclonal anti-HA-1 antibody, and then cleaved with recombinant caspase 7 (Materials and methods). The products were fractionated by
SDS-PAGE, and those containing the N-terminal sequences were detected by using a rabbit polyclonal antibody raised against a recombinant polypeptide containing
a.a. 1-65 of xPAK1. “o” indicates the anti-HA antibody used to immunoprecipitate HA-xPAK1 from the expressing embryo extract. (B) N159 does not induce
caspase 3 activation in embryo. Embryos were injected with 1.5 ng of N159 or N-K281A RNA and allowed to develop for a further 3.5 or 19 h. Total embryo
protein was then analyzed by SDS-PAGE using an antibody specific for the 17-kDa activated (cleaved) caspase 3 (see Materials and methods). To provide a positive
control of caspase 3 activation, uninjected embryos were treated in parallel with hydroxyurea to induce caspase activation apoptosis as previously described (Stack
and Newport, 1997) (see Materials and Methods). (C) Total DNA from embryos injected with 1.5 ng of N159 or N-K281 RNA and in uninjected embryos. An
EtBr-stained gel of total embryonic DNA is shown. The DNA loaded per track in the bottom panel is also indicated in terms of the numbers of embryos from which
it was extracted (No. embryo equivalents). (D) The Endogenous JNK (c-jun), exogenous xPAK (MBP), and endogenous ERK2 activities in embryos injected with
1.5 ng of N159 or N-K281 RNA and in uninjected embryos. In the case of ERK2, uninjected egg extract was also analyzed to provide a positive control of fully
activated ERK2 (ERK*) (Nebreda et al., 1995). Lower panel shows the quantitation of exogenous xPAK and endogenous JNK kinase activities relative to uninjected
controls. Quantitation is given for the assays in the upper panel, but is typical of six independent experiments. (E) Endogenous JNK can be activated by an active
form of MEKK1 (MEKK1N). Embryos were injected at the two-cell stage with RNAs expressing the indicated proteins and extracts prepared and assayed 3.5 h
later exactly as in (D). While MEKK1N induced a 3-fold activation of endogenous JNK, the highly active form N159 failed to do so as did wild type xPAK1
(wt) and kinase dead full-length xPAK1.
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Fig. 5. (A) N159 phosphorylation of total embryo protein. N159 immunoprecipitated from expressing embryos or an immunoprecipitate from uninjected
embryos (uninjected) were used to phosphorylate total protein from uninjected embryos. The autoradiograph shows phosphorylation of many proteins by
endogenous kinases. However, differential phosphorylation due to N159 can be seen for bands in the region of 50 and 20 kDa. (B) N159 phosphorylates
recombinant xMLC at serine 19 and threonine 18 in vitro. Recombinant xMLC and xMLC-S19A and -TS18/19AA were used as substrates for N159 or
the kinase dead N-K281A and then fractionated by SDS-PAGE and the gel autoradiographed. The N-terminal sequence of xMLC (Bresnick et al., 1995)
and the position of the T18A and S19A mutations are shown. (C) N159 phosphorylates xMLC and xMHC-A within native Xenopus myosin II hexamer.
Purified Xenopus myosin II was phosphorylated in vitro with N159 or the kinase dead N-K281A and phosphorylation levels determined by autoradiog-
raphy after SDS-PAGE fractionation (see Materials and methods). “Native” refers to the undenatured myosin II substrate and “Denatured” to the urea
denatured myosin II. After myosin denaturation, xMHC-A becomes insoluble and hence is no longer available to the kinase, while xMLC is released into
free solution. (D) In vivo phosphorylation of myosin II in N159 versus NK281A-injected embryos. Two-cell embryos were injected with RNAs expressing
N159 or kinase dead N-K281A and [32P]ATP and allowed to develop for 3 h. Myosin II was then immunoprecipitated with anti-xMHC-A-specific
antibody (rendering it homogeneous as judged by gel staining), fractionated by SDS-PAGE, and transferred to membrane. The membrane was first analyzed
for 32P incorporation by phosphoimaging and then the same membrane probed with both anti-xMHC-A- and xMLC-specific antibodies. Top and bottom
panels show 32P incorporation into bands corresponding in size with xMHC-A and xMLC, respectively, while the middle panel shows the recovery of
xMHC-A as detected using the anti-MHC-A antibody. “?” indicates labeled bands of unknown identity coimmunoprecipitated with myosin II. (E)
Quantitation of in vivo myosin II labeling experiments, average results for two independent experiments are given relative to the NK281A control injections.
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Fig. 6. Inhibition of myosin II abrogates blastomere fragmentation and necrosis induced by activated xPAK1. (A) Two-cell uninjected embryos were cultured
for 2 h in the indicated concentrations of BDM. During this time, 4 cell divisions occurred in the untreated (0 mM) embryos, which reached the 32-cell stage,
3 cells divisions in 10 mM BDM giving 16 cells and two divisions in 30 mM BDM giving eight cells. (B) Two-cell embryos were injected with 0.5 or 1.5
ng of N159 mRNA and then either cultured in the absence (0 mM) or presence (300 mM) of BDM. The insets in the left hand panels of (B) show an injected
embryo at higher magnification.
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with apoptotic blebbing in human cell cultures (Mills et al.,
1998). When the stoichiometry of endogenous xMLC phos-
phorylation in embryo was determined (see Materials and
methods), it revealed that around 60% of the xMLC mole-
cules were singly phosphorylated in N159-injected em-
bryos, while no more than 15–20% were phosphorylated in
the control N-K281A-injected embryos. A certain level of
xMLC phosphorylation is to be expected in the actively
dividing embryos. However, a greater than 50% phosphor-
ylation of xMLC in the presence of N159 strongly sug-
gested that activation of myosin II might in large part
explain the embryo fragmentation we observed.
XPAK1-induced blastomere fragmentation is abrogated by
an inhibitor of myosin II
The xPAK1 (N159) phosphorylation of xMLC would
be expected to activate the actin-dependent ATPase activity
of myosin II and this would conceivably lead to cell frag-
mentation by driving a reorganization of cytoskeletal acto-
myosin. Indeed, it has been previously suggested that apo-
ptotic blebbing in mammalian cells is the direct result of
myosin II activation (Mills et al., 1998). However, these
authors were unable to decouple blebbing from the other
events occuring during apoptosis. To determine whether
myosin II activation was essential for the blastomere frag-
mentation induced by activated xPAK1, we used 2,3-bu-
tanedione monoxime (BDM), an inhibitor of myosin II
function (Cramer and Mitchison, 1995, and references
therein, but see also Ostap, 2002; Titus, 2003). Myosin II
function is essential for the normal actomyosin cytoskeleton
movements associated with cell division (Maciver, 1996).
Thus, we first determined the concentration of BDM nec-
essary to fully inhibit embryo cell division. When two-cell
embryos were cultured with 10, 30, or 100 mM (data not
shown) BDM for 2 h, cell division was slowed in a dose-
dependent manner (Fig. 6A). However, full inhibition of
cell division was not observed until 300 mM BDM. Though
this concentration is higher than has been used in other
systems, Xenopus embryos are surrounded by a relatively
impermeable vitelline membrane. Thus, the in embryo
BDM concentration was very probably significantly less
than that of the culture medium. Consistent with this, the
drug ML-7 was also ineffective when added to the culture
medium, though it functioned effectively when injected (see
below; injection of BDM was not an alternative due to its
Fig. 7. xPAK (N159)-induced cell fragmentation and xPAK1 kinase
activity are both inhibited in embryo by ML-7. (A) Uninjected stage 6
embryos and the same embryos after being injected at the two-cell stage
with 500 ng of N159 RNA in the presence and absence of ML-7. These
same inhibitory effects of ML-7 were reproduced in four independent
experiments. The concentration of ML-7 indicated is the effective concen-
tration achieved in the embryo. (B) N159 was immunoprecipitated from
extracts of the embryos in (A) and was subjected to xPAK kinase assays
(Materials and methods) using recombinant MLC as substrate. The upper
panel shows N159 autophosphorylation, while the middle panel shows
MLC substrate phosphorylation. Note the complete inhibition of activity by
30 M ML-7. As control for equal subtrate input, the lower panel shows
the immunoblotting of the center panel with anti-MLC antibody. The
relative 32P incorporation into xMLC (middle panel) normalized to the
input xMLC (lower panel) is given below each track.
275N. Bisson et al. / Developmental Biology 263 (2003) 264–281
low solubility). In vitro, the ATPase activity of purified
mammalian myosin II unassociated with actin was shown to
be reduced to 5.5% of control at 10 mM BDM (Cramer and
Mitchison, 1995). Presumably, full inhibition would require
a significantly higher concentration. Thus, at least 30 mM
BDM was required to inhibit myosin contractility in mouse
cells (Chen et al., 2002) and 50 mM only partially inhibited
basal protein targeting even in dechorionated Drosophila
larvae (Peng et al., 2000). Though recent findings have
questioned the mechanism by which BDM functions, there
is little doubt that it inhibits processes requiring myosin II
activity (Titus, 2003).
When embryos were injected with the activated N159
form of xPAK1, as expected, rapid blastomere fragmenta-
tion was observed (Fig. 6B). However, when these embryos
were allowed to develop in the presence of 300 mM BDM,
fragmentation was completely inhibited as was cell divi-
sion. This strongly suggested that myosin II function was
essential for the blastomere fragmentation induced by acti-
vated xPAK1 (N159).
XPAK1-induced blastomere fragmentation is also
abrogated by ML-7, an inhibitor of MLCK
Inhibitors of MLCK, such as ML-7 (Calbiochem), one of
the most specific small molecule inhibitors, have been
shown to abrogate apoptotic blebbing and cell fragmenta-
tion in cultured cells (Mills et al., 1998). When N159-
injected embryos were coinjected with ML-7 to give a final
in embryo concentration of 10 M, blastomere fragmenta-
tion was greatly inhibited and was fully abrogated at 30 M
ML-7 (Fig. 7A). This again strongly suggested that N159-
induced blastomere fragmentation and apoptotic blebbing
were the same or very closely related phenomena. However,
PAK activation has been reported to inhibit MLCK activity
(Daniels and Bokoch, 1999), hence it seemed unlikely that
the ML-7 inhibition of blastomere fragmentation was the
result of MLCK inhibition. However, given the close cor-
respondence between the substrate specificities of xPAK1
and MLCK, it seemed reasonable to suppose that the PAKs
might also be targets of ML-7 inhibition. Extracts from
N159-injected embryos and embryos coinjected or not
with ML-7 were assayed for xPAK1 kinase activity using
MLC as substrate and by following N159 autophosphor-
ylation (Fig. 7B). It was found that by 10 M ML-7,
autophosphorylation of N159 and, to a lesser extent, MLC
phosphorylation were detectably inhibited, while at 30 M
ML-7, both these activities were undetectable. Thus, ML-7
abrogation of N159-induced blastomere fragmentation is
due to inhibition of the catalytic activity of N159. The
observation that ML-7 inhibits xPAK1 at the same concen-
tration as reported for inhibition of MLCK suggests that
previous data on the role of MLCK in apoptotic blebbing
(Mills et al., 1998) may require reconsideration.
A major reorganization of the pigment and actin cortex
occurs during normal apoptosis
Xenopus embryos are incompetent to activate the
caspase-dependent apoptotic pathway before the midblas-
tula transition (Sible et al., 1997; Stack and Newport, 1997).
However, blocking DNA replication during early develop-
ment using hydroxyurea (HU) has been shown to lead to a
homogeneous activation of caspase dependent apoptosis
after the midblastula transition (8 h postfertilization) (Howe
et al., 1995). Soon after the midblastula stage, HU-treated
embryos displayed an extensive rearrangement of animal
pole pigment granules (Fig. 8A; 10 h). Pigment concen-
trated centrally on the surface of each blastomere, producing
a “giraffe”-like coloring pattern. Since the embryonic pig-
ment is imbedded in the cortical actin layer, its rearrange-
ment indicated a reorganization of this cortical actin. As
apoptosis progressed, pigment-free blastomeres, predomi-
nantly from the (unpigmented) vegetal pole, delaminated
and filled the space between the embryo surface and the
vitelline membrane, partially masking the embryo (see
white cells in Fig. 8A, 11 h). The giraffe coloring phenotype
resembled the initial effects of xPAK1 activation (Fig. 1B),
both showing a rearrangement, and a gradual disappearance
of embryonic pigment from the animal pole blastomeres,
though in the case of the apoptotic embryos, the effect
occurred more slowly. As with the effects of activated
xPAK1, development of the “giraffe” coloring phenotype
was abrogated by incubation in the myosin II inhibitor
BDM (Fig. 8A), indicating a requirement for myosin II
activity.
When apoptotic embryos were cryosectioned it became
apparent that the loss of pigment from the outer blastomeres
was due to its internalization (see “Pigment Flows” in Fig.
8Bii–iv, “HU Treated”). In normal embryos, the pigment
layer was clearly visible as an optically dense, thin apical
layer (Figure 8Bi, Not Treated). Only a thin cortical layer of
F-actin was just visible on the lateral and basal faces of the
blastomeres of the outer cell layer. In apoptotic embryos (11
h postfertilization), the apical pigment layer had greatly
thinned, the pigment having concentrated centrally on the
apical surface of the blastomeres, giving the giraffe pattern.
Most surprisingly, the pigment was seen to streak from
these concentrations deep into the cytoplasm in a basal
direction. This concentration and internalization of pigment
was associated with the formation of a thick apical F-actin
“cap.” The actin caps often spread between adjacent blas-
tomeres, which appeared to be stretched and drawn or
crawling over a central delaminating blastomere (e.g., see
Fig. 8Biii and iv). This stretching probably correlated with
the elongation of surface blastomeres seen in Fig. 8A, 11 h.
Thus, embryonic apoptosis, like the expression of activated
xPAK1, showed both internalization of surface pigment
associated with polymerization of thick cortical actin layers.
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xPAK1 is cleaved and myosin II activated during
embryonic apoptosis
By homology with hPAK2 (Rudel and Bokoch, 1997),
caspase 3/7 cleavage of xPAK1 was predicted to yield a
20.7-kDa N-terminal fragment and a C-terminal catalytic
fragment of 34.8 kDa (Fig. 9A). Western blot analysis of
protein extracts with an anti-xPAK (a.a. 1–63) affinity-
purified antibody showed that endogenous xPAK1 was
cleaved in apoptotic embryos. However, we were unable to
detect the predicted N-terminal cleavage product (either
with this antibody or with another anti-N-terminal antibody
kindly provided by N. Morin), suggesting that the caspase
product was unstable. We have been unable to date to raise
an antibody to the catalytic domain of xPAK1. However,
extracts from apoptotic (HU) but not from normal (NT)
embryos were able to release the predicted 36-kDa caspase
fragment from 35S-labeled, in vitro translated xPAK1-myc
(Fig. 9C). This fragment was also recovered by immuno-
precipitation using an anti-Myc antibody (Sigma), showing
that it did indeed correspond with the predicted C-terminal
catalytic domain polypeptide. To determine whether this
cleavage product was active, C-terminally Myc-tagged
xPAK1 was again incubated in extracts from apoptotic and
normal embryos, the C-terminal fragment recovered by im-
munoprecipitation with the anti-Myc antibody, as in Fig.
9C, but then assayed for kinase activity (Fig. 9D). Treat-
ment with the apoptotic extract significantly enhanced the
kinase activity assayed on MLC as compared with treatment
with the normal embryo extract.
When the level of serine 19 phosphorylation of endoge-
nous xMLC was also analyzed in apoptotic embryos, it was
found to be significantly (1.3 times) higher than in normal
embryos. Thus, during HU-induced embryonic apoptosis,
the cleavage and activation of xPAK1 correlated with an
increase in the phosphorylation of endogenous MLC at
serine 19.
Discussion
By expressing the catalytic domain of xPAK1 in Xeno-
pus embryos at a stage when they are still refractory to the
onset of apoptosis, we have shown that the caspase cleavage
product of this kinase is sufficient to induce cell fragmen-
tation closely resembling the production of apoptotic bod-
ies. Cell fragmentation occured almost immediately (30
min after mRNA injection) and in the absence of caspase
activation, JNK activation, DNA degradation, externaliza-
tion of phosphatidyl-serine, or changes in membrane per-
meability. Cell fragmentation was preceded by a rapid re-
organization and internalization of embryonic pigment
granules, suggesting a major rearrangement of cortical ac-
tin. Cell fragments were found to be surrounded by a thick
F-actin cortex. We conclude that xPAK1 activation is suf-
ficient for apoptotic body formation independently of other
apoptotic events. We further showed that activated xPAK1
directly phosphorylates recombinant myosin regulatory
light chain (xMLC) at threonine 18 and serine 19 and
efficiently phosphorylates xMLC within native Xenopus
myosin II in vitro. Phosphorylation of xMLC at serine 19
has been shown to activate the ATPase activity of myosin II
(Bresnick et al., 1995). Expression of activated xPAK1 also
led to very significant hyperphosphorylation of xMLC in
vivo. BDM, an inhibitor of myosin II activity, completely
prevented xPAK1 induced cell fragmentation. Finally, we
showed that ML-7, previously suggested to inhibit apoptotic
cell blebbing by acting on myosin light chain kinase
(MLCK), abrogated xPAK1-induced blastomere fragmenta-
tion and inhibited xPAK1 activity. Thus, our data are con-
sistent with direct activation of myosin II by activated
xPAK1 and with this event being necessary for a cell frag-
mentation resembling apoptotic body formation.
We have also shown that several characteristics of “nat-
ural” apoptosis in Xenopus embryos resemble those induced
by the expression of activated xPAK1. The first indication
of apoptosis was a BDM inhibitable rearrangement of cor-
tical pigment granules, indicating a reorganization of corti-
cal actin. Pigment was internalized into the blastomere
cytoplasm, and this process correlated with the formation of
a thick cortical actin “cap.” xPAK1 was cleaved and acti-
vated during normal apoptosis, and this activation corre-
sponded with an increase in the level of endogenous xMLC
phosphorylation on serine 19.
Despite a considerable number of PAK targets having
been identified, including MLCK, LIM-kinase, and myosin
(Daniels and Bokoch, 1999), none have as yet been shown
to have any functional significance in apoptosis. MLCK is
thought to be the major regulator of myosin II activity;
however, PAK phosphorylation of MLCK leads to its inac-
tivation. On the other hand, PAK itself is very probably able
to take over the role of MLCK and to independently activate
the cellular myosin II (Ramos et al., 1997; Tuazon and
Traugh, 1984; and the present study). At the same time,
PAK activation of LIM-kinase promotes actin polymeriza-
tion via the inactivation of cofilin and more recently PAK
phosphorylation of filamin has also been shown to stimulate
actin polymerization and branching (Vadlamudi et al.,
2002). Thus, activation of PAK during apoptosis activates
both the myosin II ATPase and very probably actin poly-
merization. It would therefore have the potential to induce
the major cortical actin reorganization seen during apoptotic
body formation.
JNK activation has been shown to induce apoptosis un-
der certain circumstances (e.g., Leppa¨ and Bohmann, 1999).
Since under certain conditions the PAKs induce activation
of this kinase, we were surprised to find that the highly
active xPAK1 catalytic domain did not induce JNK activa-
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tion in embryo, at least not for the first 3.5 h after micro-
injection, by which time cell fragmentation was well ad-
vanced. At the same embryonic stage, endogenous JNK
could be activated by injection of constitutively active
MKK4, showing that this was not due to a lack of compe-
tence of the JNK cascade. It should be noted that the
literature correlating PAK activity with JNK activation is
far from equivocal. Overexpression of the PAKs have been
found to both enhance (Bagrodia et al., 1995; Brown et al.,
1996; Frost et al., 1996) and to inhibit JNK activity (Frost et
al., 1996; Siow et al., 1997; Teramoto et al., 1996; Westwick
et al., 1997). Furthermore, we have found that none of the
full-length constitutively active forms of xPAK1 studied in
our laboratory are able to activate JNK (Poitras et al., 2003;
L.P. and N.I., unpublished data). The only exception oc-
cured 18 h after xPAK1 injection and more than 17.5 h after
cell fragmentation first became apparent (Fig. 4D). By this
stage, large regions of the injected embryos were in a very
advanced state of degradation and displayed no discernable
cellular structure. JNK activation was clearly a secondary
effect and perhaps related to the stress responses associated
with the advanced stage of cell death. If similar delayed
effects also occur in cell transfection experiments, these
might explain why it has not been possible to reach a consen-
sus concerning the function of the PAKs in the JNK pathway.
Our data also demonstrate that caspase activation of xPAK1
is sufficient to determine a process closely resembling the cell
fragmentation from which apoptosis first took its name (Kerr et
al., 1972). xPAK1 targets, such as LIM kinase and filamin,
may also play a role in this process by regulating actin branch-
ing and polymerization (Daniels and Bokoch, 1999; Vadla-
mudi et al., 2002). However, our data strongly support the
Fig. 8. Apoptosis in Xenopus embryos is associated with actin polymer-
ization and resorption of pigment that can be inhibited by BDM. (A)
Embryos were treated with 30 mM hydroxyurea (HU) to block DNA
replication and hence induce apoptosis after the midblastula transition
(Stack and Newport, 1997) (see Materials and methods). HU-treated em-
bryos are shown at 10 and 11 h postfertilization in comparison with a not
treated control embryo and an embryo treated with HU until 8 h postfer-
tilization and then transferred to 100 mM BDM, until 11 h postfertilization.
The data are representative of three independent experiments. (B) Embryos
treated as in (A) were fixed 11 h postfertilization, cryosectioned, and
stained for F-actin with Alexafluor594-phalloidin (Molecular Probes)
(Drechsel et al., 1997). “Visible” images show standard transmission mi-
crograms and “F-actin” the Alexafluor594 fluorescence. (i) The embryonic
pigment is clearly seen in the apical cortex of the outermost cells of the
normal (Not Treated) embryos. (ii–iv) This pigment was rapidly internal-
ized into the cytoplasm, and this process was associated with the formation
of a heavy F-actin “cap,” explaining the “giraffe” patterning of the apo-
ptotic embryos (A). As a result of the induction of apoptosis, the Not
Treated embryos had undergone one division more than the HU-treated
ones by 11 h postfertilization. For ease of comparison, the microgram in (i)
has therefore been enlarged 1.4 relative to (ii) to approximately account
for the resulting difference in blastomere size. The scale bar indicates true
size.
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novel suggestion that direct activation of myosin II by xPAK1
is an essential step in apoptotic body formation.
Acknowledgments
We thank Robert Adelstein for anti-Xenopus MHC-A
and MHC-B antibodies and for his aid and advice on the use
of these reagents and N. Morin for providing xPAK1 anti-
body. We would also like to thank John Grose and Jacques-
Landry for providing anti-ERK2 and anti-HA-1 antibodies
and for the protocols for kinase assays and Guy Poirier for
the very little caspase 7 he could spare. This work was
supported in Que´bec by an operating grant from the Na-
tional Cancer Institute of Canada with funds from the Ca-
Fig. 9. xPAK1 is cleaved to release its kinase domain during hydroxyurea (HU)-induced apoptosis. (A) The predicted caspase cleavage products of 20.7 and
34.8 kDa and the polypeptide used to raise and affinity-purify the anti-xPAK1 antibody are indicated beneath a diagrammatic representation of xPAK1. (B)
Protein extracts from not treated (NT) and hydroxyurea (HU) treated embryos were probed for xPAK1 by Western blot. The analysis was repeated
independently more than four times and cleavage and loss of full-length xPAK1 was seen in all assays. (C) In vitro translated 35S-methionine labeled
C-terminally myc-tagged full-length xPAK1 was incubated in whole protein extracts from untreated (NT) and apoptotic (HU) embryos for the times indicated
before SDS-PAGE analysis (Materials and methods). The predicted C-terminal 36-kDa peptide containing the kinase domain was detected only in the
apoptotic extracts and was recovered by anti-myc immunoprecipitation (myc IP). The assay was repeated independently and gave exactly the same cleavage.
(D) C-terminally myc-tagged xPAK1 was expressed in embryo and recovered by immunoprecipitation. It was then incubated with extracts from hydroxyurea
(HU) or not treated (NT) embryos, and subjected to kinase assay using MLC as substrate. (E) The level of phosphorylation of MLC in apoptotic (HU) and
normal (NT) embryos was determined by using a phospho-S19 MLC-specific antibody (Cell Signaling Inc.). The upper and lower panels show the same blots
probed phospho-S19 MLC antibody or an anti-MLC antibody. The left panels show the analysis of recombinant-xPAK1 phosphorylated or unphosphorylated
recombinant MLC. The right panels show the same analysis on MLC from HU-treated and not treated embryos. An increase in xMLC phosphorylation was
observed in the two independent experiments performed. The band intensities were determined by using ECL (Roche) and a digital camera (AlphaImager
Inc). The ratios of phospho-S19 MLC (MLC-S19-P) to Bulk MLC (MLC Bulk) are given after normalization to the ratio for the untreated (NT) embryos.
279N. Bisson et al. / Developmental Biology 263 (2003) 264–281
nadian Cancer Society, a FCAR-FRSQ Sante´ scholarship
(to L.P), and a NSERC scholarship (to S.J.).
References
Bagrodia, S., De´rijard, B., Davis, R.J., Cerione, R.A., 1995. Cdc42 and
PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated
protein kinase activation. J. Biol. Chem. 270, 27995–27998.
Bhatia-Dey, N., Adelstein, R.S., Dawid, I.B., 1993. Cloning of the cDNA
encoding a myosin heavy chain B isoform of Xenopus nonmuscle
myosin with an insert in the head region. Proc. Natl. Acad. Sci. USA
90, 2856–2859.
Bokoch, G.M., 2003. Biology of the p21-activated kinases. Annu. Rev.
Biochem., in press.
Bresnick, A.R., Wolff-Long, V.L., Baumann, O., Pollard, T.D., 1995.
Phosphorylation on threonine-18 of the regulatory light chain dissoci-
ates the ATPase and motor properties of smooth muscle myosin II.
Biochemistry 34, 12576–12583.
Brown, J.L., Stowers, L., Baer, M., Trejo, J., Coughlin, S., Chant, J., 1996.
Human Ste20 homologue hPAK1 links GTPases to the JNK MAP
kinase pathway. Curr. Biol. 6, 598–605.
Cau, J., Faure, S., Comps, M., Delsert, C., Morin, N., 2001. A novel
p21-activated kinase binds the actin and microtubule networks and
induces microtubule stabilization. J. Cell Biol. 155, 1029–1042.
Cau, J., Faure, S., Vigneron, S., Labbe´, J.C., Delsert, C., Morin, N., 2000.
Regulation of xenopus p21-activated kinase (X-PAK2) by Cdc42 and
maturation-promoting factor controls Xenopus oocyte maturation.
J. Biol. Chem. 275, 2367–2375.
Chen, B.H., Tzen, J.T., Bresnick, A.R., Chen, H.C., 2002. Roles of Rho-
associated kinase and myosin light chain kinase in morphological and
migratory defects of focal adhesion kinase-null cells. J. Biol. Chem. 8, 8.
Chen, Y.R., Wang, X.P., Templeton, D., Davis, R.J., Tan, T.H., 1996. The
role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultra-
violet C and gamma radiation: duration of JNK activation may deter-
mine cell death and proliferation. J. Biol. Chem. 271, 31929–31936.
Cramer, L.P., Mitchison, T.J., 1995. Myosin is involved in postmitotic cell
spreading. J. Cell Biol. 131, 179–189.
Daniels, R.H., Bokoch, G.M., 1999. p21-activated protein kinase: a crucial
component of morphological signaling? Trends Biochem. Sci. 24,
350–355.
De Mazie`re, A.M., Hage, W.J., Ubbels, G.A., 1996. A method for staining
of cell nuclei in Xenopus laevis embryos with cyanine dyes for whole-
mount confocal laser scanning microscopy. J. Histochem. Cytochem.
44, 399–402.
Dharmawardhane, S., Sanders, L.C., Martin, S.S., Daniels, R.H., Bokoch,
G.M., 1997. Localization of p21-activated kinase 1 (PAK1) to pino-
cytic vesicles and cortical actin structures in stimulated cells. J. Cell
Biol. 138, 1265–1278.
Drechsel, D.N., Hyman, A.A., Hall, A., Glotzer, M., 1997. A requirement
for Rho and Cdc42 during cytokinesis in Xenopus embryos. Curr. Biol.
7, 12–23.
Faure, S., Vigneron, S., Dore´e, M., Morin, N., 1997. A member of the
Ste20/PAK family of protein kinases is involved in both arrest of
Xenopus oocytes at G2/prophase of the first meiotic cell cycle and in
prevention of apoptosis. EMBO J. 16, 5550–5561.
Frost, J.A., Steen, H., Shapiro, P., Lewis, T., Ahn, N., Shaw, P.E., Cobb,
M.H., 1997. Cross-cascade activation of ERKs and ternary complex
factors by Rho family proteins. EMBO J. 16, 6426–6438.
Frost, J.A., Xu, S.C., Hutchison, M.R., Marcus, S., Cobb, M.H., 1996.
Actions of Rho family small G proteins and p21-activated protein
kinases on mitogen-activated protein kinase family members. Mol.
Cell. Biol. 16, 3707–3713.
Gnesutta, N., Qu, J., Minden, A., 2001. The serine/threonine kinase PAK4
prevents caspase activation and protects cells from apoptosis. J. Biol.
Chem. 276, 14414–14419.
Harden, N., Lee, J., Loh, H.Y., Ong, Y.M., Tan, I., Leung, T., Manser, E.,
Lim, L., 1996. A Drosophila homolog of the Rac- and Cdc42-activated
serine/threonine kinase PAK is a potential focal adhesion and focal
complex protein that colocalizes with dynamic actin structures. Mol.
Cell. Biol. 16, 1896–1908.
Howe, J.A., Howell, M., Hunt, T., Newport, J.W., 1995. Identification of a
developmental timer regulating the stability of embryonic cyclin A and a
new somatic A-type cyclin at gastrulation. Genes Dev. 9, 1164–1176.
Islam, N., Poitras, L., Moss, T., 2000. The cytoskeletal effector xPAK1 is
expressed during both car and lateral line development in Xenopus. Int.
J. Dev. Biol. 44, 245–248.
Jaffer, Z.M., Chernoff, J., 2002. p21-activated kinases: three more join the
Pak. Int. J. Biochem. Cell Biol. 34, 713–717.
Jakobi, R., Moertl, E., Koeppel, M.A., 2001. p21-activated protein kinase
gamma-PAK suppresses programmed cell death of BALB3T3 fibro-
blasts. J. Biol. Chem. 276, 16624–16634.
Jeffs, P., Jaques, K., Osmond, M., 1992. Cell death in cranial neural crest
development. Anat. Embryol. 185, 583–588.
Kelley, C.A., Oberman, F., Yisraeli, J.K., Adelstein, R.S., 1995. A Xeno-
pus nonmuscle myosin heavy chain isoform is phosphorylated by
cyclin-p34cdc2 kinase during meiosis. J. Biol. Chem. 270, 1395–1401.
Kelley, C.A., Sellers, J.R., Gard, G.L., Bui, D., Adelstein, R.S., 1996.
Xenopus nonmuscle myosin heavy chain isoforms have different sub-
cellular localizations and enzymatic activities. J. Cell Biol. 134, 675–687.
Kerr, J.F., Wyllie, A.H., Currie, A.R., 1972. Apoptosis: a basic biological
phenomenon with wide-ranging implications in tissue kinetics. Br. J.
Cancer 26, 239–257.
Lee, N., MacDonald, H., Reinhard, C., Halenbeck, R., Roulston, A., Shi,
T., Williams, L.T., 1997. Activation of hPAK65 by caspase cleavage
induces some of the morphological and biochemical changes of apo-
ptosis. Proc. Natl. Acad. Sci. USA 94, 13642–13647.
Leppa¨, S., Bohmann, D., 1999. Diverse functions of JNK signaling and
c-Jun in stress response and apoptosis. Oncogene 18, 6158–6162.
Liu, Z.G., Hsu, H.L., Goeddel, D.V., Karin, M., 1996. Dissection of TNF
receptor 1 effector functions: JNK activation is not linked to apoptosis
while NF-kappaB activation prevents cell death. Cell 87, 565–576.
Maciver, S.K., 1996. Myosin II function in non-muscle cells. BioEssays
18, 179–182.
Manser, E., Huang, H.Y., Loo, T.H., Chen, X.Q., Dong, J.M., Leung, T., Lim,
L., 1997. Expression of constitutively active alpha-PAK reveals effects of
the kinase on actin and focal complexes. Mol. Cell. Biol. 17, 1129–1143.
Martin, S.J., Green, D.R., Cotter, T.G., 1994. Dicing with death: dissecting the
components of the apoptosis machinery. Trends Biochem. Sci. 19, 26–30.
Martin, S.J., Reutelingsperger, C.P., McGahon, A.J., Rader, J.A., van
Schie, R.C., LaFace, D.M., Green, D.R., 1995. Early redistribution of
plasma membrane phosphatidylserine is a general feature of apoptosis
regardless of the initiating stimulus: inhibition by overexpression of
Bcl-2 and Abl. J. Exp. Med. 182, 1545–1556.
Mills, J.C., Stone, N.L., Erhardt, J., Pittman, R.N., 1998. Apoptotic mem-
brane blebbing is regulated by myosin light chain phosphorylation.
J. Cell. Biol. 140, 627–636.
Mitchison, T.J., Cramer, L.P., 1996. Actin-based cell motility and cell
locomotion. Cell 84, 371–379.
Nebreda, A.R., Gannon, J.V., Hunt, T., 1995. Newly synthesized protein(s)
must associate with p34cdc2 to activate MAP kinase and MPF during
progesterone-induced maturation of Xenopus oocytes. EMBO J. 14,
5597–5607.
Nieuwkoop, P.D., Faber, J., 1967. Normal Table of Xenopus laevis (Dau-
din): A systematical and chronological survey of the development from
the fertilized egg till the end of metamorphosis. North-Holland Pub-
lishing Company, Amsterdam.
Obermeier, A., Ahmed, S., Manser, E., Yen, S.C., Hall, C., Lim, L., 1998.
PAK promotes morphological changes by acting upstream of Rac.
EMBO J. 17, 4328–4339.
Ostap, E.M., 2002. 2,3-Butanedione monoxime (BDM) as a myosin inhib-
itor. J. Muscle Res. Cell Motil. 23, 305–308.
280 N. Bisson et al. / Developmental Biology 263 (2003) 264–281
Peng, C.Y., Manning, L., Albertson, R., Doe, C.Q., 2000. The tumour-
suppressor genes lgl and dlg regulate basal protein targeting in Dro-
sophila neuroblasts. Nature 408, 596–600.
Peter, M.E., Heufelder, A.E., Hengartner, M.O., 1997. Advances in apo-
ptosis research. Proc. Natl. Acad. Sci. USA 94, 12736–12737.
Poitras, L., Jean, S., Islam, N., Moss, T., 2003. PAK interacts with NCK
and MLK2 to regulate the activation of jun N-terminal kinase. FEBS
Lett. 543, 129–135.
Ramos, E., Wysolmerski, R.B., Masaracchia, R.A., 1997. Myosin phos-
phorylation by human cdc42-dependent S6/H4 kinase/gammaPAK
from placenta and lymphoid cells. Recept. Signal. Transduct. 7, 99–110.
Rooney, R.D., Tuazon, P.T., Meek, W.E., Carroll Jr., E.J., Hagen, J.J.,
Gump, E.L., Monnig, C.A., Lugo, T., Traugh, J.A., 1996. Cleavage
arrest of early frog embryos by the G protein-activated protein kinase
PAK I. J. Biol. Chem. 271, 21498–21504.
Rudel, T., Bokoch, G.M., 1997. Membrane and morphological changes in
apoptotic cells regulated by Caspase-mediated activation of PAK2.
Science 276, 1571–1574.
Schu¨rmann, A., Mooney, A.F., Sanders, L.C., Sells, M.A., Wang, H.G.,
Reed, J.C., Bokoch, G.M., 2000. p21-activated kinase 1 phosphorylates
the death agonist Bad and protects cells from apoptosis. Mol. Cell.
Biol. 20, 453–461.
Sells, M.A., Knaus, U.G., Bagrodia, S., Ambrose, D.M., Bokoch, G.M.,
Chernoff, J., 1997. Human p21-activated kinase (Pak1) regulates actin
organization in mammalian cells. Curr. Biol. 7, 202–210.
Sible, J.C., Anderson, J.A., Lewellyn, A.L., Maller, J.L., 1997. Zygotic
transcription is required to block a maternal program of apoptosis in
Xenopus embryos. Dev. Biol. 189, 335–346.
Siow, Y.L., Kalmar, G.B., Sanghera, J.S., Tai, G., Oh, S.S., Pelech, S.L.,
1997. Identification of two essential phosphorylated threonine residues
in the catalytic domain of Mekk1: indirect activation by Pak3 and
protein kinase C. J. Biol. Chem. 272, 7586–7594.
Smith, D.B., Corcoran, L.M., 1991. Protein expression. in: Ausubel, E.M.,
Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Seidman, J.G.,
Smith, J.A., Struhl, K. (Eds.), Current Protocols in Molecular Biology.
Greene Publishing Associates & Wiley-Interscience, New York.
Song, Z.W., Steller, H., 1999. Death by design: mechanism and control of
apoptosis. Trends Biochem. Sci. 24, M49–M52.
Souopgui, J., Solter, M., Pieler, T., 2002. XPak3 promotes cell cycle
withdrawal during primary neurogenesis in Xenopus laevis. EMBO J.
21, 6429–6439.
Stack, J.H., Newport, J.W., 1997. Developmentally regulated activation of
apoptosis early in Xenopus gastrulation results in cyclin A degradation
during interphase of the cell cycle. Development 124, 3185–3195.
Stefanovsky, V.Y., Pelletier, G., Hannan, R., Gagnon-Kugler, T., Roth-
blum, L.I., Moss, T., 2001. An immediate response of ribosomal
transcription to growth factor stimulation in mammals is mediated by
ERK phosphorylation of UBF. Mol. Cell 8, 1063–1073.
Teramoto, H., Coso, O.A., Miyata, H., Igishi, T., Miki, T., Gutkind, J.S., 1996.
Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the
c-Jun N-terminal kinase stress-activated protein kinase pathway: a role for
mixed lineage kinase 3 protein-tyrosine kinase 1, a novel member of the
mixed lineage kinase family. J. Biol. Chem. 271, 27225–27228.
Titus, M.A., 2003. Caveat experimentor—is your myosin really inhibited?
Nat. Cell Biol. 5, 95.
Tuazon, P.T., Traugh, J.A., 1984. Activation of actin-activated ATPase in
smooth muscle by phosphorylation of myosin light chain with protease-
activated kinase I. J. Biol. Chem. 259, 541–546.
Vadlamudi, R.K., Li, F., Adam, L., Nguyen, D., Ohta, Y., Stossel, T.P.,
Kumar, R., 2002. Filamin is essential in actin cytoskeletal assembly
mediated by p21-activated kinase I. Nat. Cell Biol. 4, 681–690.
Vernes, I., Haanen, C., Steffens-Nakken, H., Reutelingsperger, C., 1995. A
novel assay for apoptosis. Flow cytometric detection of phosphatidyl-
serine expression on early apoptotic cells using fluorescein labelled
Annexin V. J. Immunol. Methods 184, 39–51.
Westwick, J.K., Lambert, Q.T., Clark, G.J., Symons, M., Van Aelst, L.,
Pestell, R.G., Der, C.J., 1997. Rac regulation of transformation, gene
expression, and actin organization by multiple, PAK-independent path-
ways. Mol. Cell Biol. 17, 1324–1335.
Wilson, I.A., Niman, H.L., Houghten, R.A., Cherenson, A.R., Connolly,
M.L., Lerner, R.A., 1984. The structure of an antigenic determinant in
a protein. Cell 37, 767–778.
Zhang, S.J., Han, J.H., Sells, M.A., Chernoff, J., Knaus, U.G., Ulevitch,
R.J., Bokoch, G.M., 1995. Rho family GTPases regulate p38 mitogen-
activated protein kinase through the downstream mediator Pak1.
J. Biol. Chem. 270, 23934–23936.
Zhao, Z.S., Manser, E., Chen, X.Q., Chong, C., Leung, T., Lim, L., 1998.
A conserved negative regulatory region in alphaPAK: inhibition of
PAK kinases reveals their morphological roles downstream of Cdc42
and Rac1. Mol. Cell. Biol. 18, 2153–2163.
281N. Bisson et al. / Developmental Biology 263 (2003) 264–281
